NCT05759377

Brief Summary

Abiomed Impella V-A ECMO AUTO Mode - Observational Study

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 22, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 8, 2023

Completed
7 months until next milestone

Study Start

First participant enrolled

October 11, 2023

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 3, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 3, 2025

Completed
Last Updated

July 3, 2025

Status Verified

July 1, 2025

Enrollment Period

1.6 years

First QC Date

February 22, 2023

Last Update Submit

July 2, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Gather clinical event data

    Collection of clinical events to serve as a database for an in-silico post-hoc analysis of the V-A ECMO AUTO Mode algorithm

    Until one of the devices is permanently weaned, on average 5 days

  • Usability assessment

    Confirmation of usability and ease of use by collection of user data and operational console data

    Until study completion, an average of 1 year

Interventions

The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings ("events") has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients treated with concomitant VA ECMO and Impella CP® heart pump (ECpella) due to severe acute heart failure by any cause (e.g. cardiogenic shock in acute myocardial infarction, cardiac arrest, myocarditis).

You may qualify if:

  • Patients with ongoing or planned ECpella therapy

You may not qualify if:

  • Age \< 18 years
  • Treatment with other than VA ECMO setup
  • Treatment with Impella CP® heart pump only

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Uniklinik RWTH Aachen

Aachen, North Rhine-Westphalia, 52074, Germany

Location

HDZ NRW

Bad Oeynhausen, North Rhine-Westphalia, 32545, Germany

Location

Herzzentrum Dresden GmbH

Dresden, Saxony, 01307, Germany

Location

Universitäres Herz- und Gefäßzentrum Hamburg

Hamburg, 20251, Germany

Location

UKGM Universtitätsklinikum Marburg

Marburg, Germany

Location

Krankenhaus der Barmherzigen Brüder - Herzzentrum Trier

Trier, Germany

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Alexander Kersten, MD

    Uniklinik RWTH Aachen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 22, 2023

First Posted

March 8, 2023

Study Start

October 11, 2023

Primary Completion

June 3, 2025

Study Completion

June 3, 2025

Last Updated

July 3, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations